Global Paromomycin (CAS 7542-37-2) Market Size By Type (95% Purity Type, 96% Purity Type), By Application (Paromomycin Sulfate, Paromomycin Injection), By Region, And Segment Forecasts, 2023 to 2032

The Global Paromomycin (CAS 7542-37-2) Market was valued at USD 98.7 million in 2023 and is projected to reach USD 163.1 million by 2031, growing at a CAGR of 6.7% during the forecast period of 2023–2031. Paromomycin, an aminoglycoside antibiotic, is widely used for the treatment of parasitic infections such as leishmaniasis and amoebiasis. The market is experiencing steady growth driven by the rising prevalence of neglected tropical diseases, increased government focus on antimicrobial resistance (AMR), and wider access to generic medications in developing regions.

Drivers

1. Growing Burden of Parasitic Infections:

Regions such as South Asia, Sub-Saharan Africa, and parts of Latin America face high incidences of diseases like visceral leishmaniasis and amoebiasis. Paromomycin has gained traction as a cost-effective treatment, particularly in endemic regions, fueling its demand.

2. Global Initiatives to Combat Neglected Tropical Diseases (NTDs):

Support from organizations like WHO and NGOs promoting access to essential medicines has significantly boosted the availability and application of Paromomycin, contributing to overall market growth.

3. Increasing Generic Drug Production:

The rise of low-cost manufacturing, particularly in India and China, has helped improve the availability and affordability of Paromomycin globally, especially in low- and middle-income countries.

Restraints

1. Side Effects and Limited Spectrum:

Paromomycin, like other aminoglycosides, is associated with nephrotoxicity and ototoxicity. These side effects restrict its usage in certain patient populations and contribute to cautious clinical adoption.

2. Regulatory Hurdles in Approval:

Gaining regulatory approval in certain developed markets remains challenging due to stringent drug safety and efficacy requirements, limiting market penetration in some geographies.

Opportunity

1. Expansion in Unmet Markets:

Several countries in Africa and Asia still lack access to cost-effective antiparasitic treatments. Expanding manufacturing and distribution capabilities in these regions presents strong growth potential for market participants.

2. Use in Combination Therapies:

Clinical research exploring combination therapies involving Paromomycin for resistant parasitic strains opens avenues for expanding the drug’s usage beyond its traditional applications.

Market by System Type Insights

By formulation type, oral formulations dominated the market in 2023, accounting for the majority of prescriptions due to ease of administration and widespread use for intestinal infections. However, injectable formulations are anticipated to grow faster during the forecast period, driven by their application in treating visceral leishmaniasis, where systemic delivery is essential for efficacy.

Market by End-use Insights

Hospitals led the market in 2023 due to the critical nature of parasitic infections requiring inpatient treatment and the availability of injectables in clinical settings. Retail pharmacies, however, are expected to witness significant growth as access to oral Paromomycin increases through public health programs and over-the-counter availability in endemic areas.

Market by Regional Insights

The Asia-Pacific region dominated the global Paromomycin market in 2023, with countries like India, Bangladesh, and Nepal being major consumers due to the high burden of parasitic diseases and government-led eradication programs. Africa is expected to exhibit the highest growth rate during the forecast period, owing to rising healthcare awareness, international aid, and strengthening distribution channels for essential medications.

Competitive Scenario

Key players operating in the global Paromomycin market include Pfizer Inc., Ipca Laboratories Ltd., Strides Pharma Science Ltd., Cipla Ltd., Endo International plc, and Lupin Pharmaceuticals, Inc. These companies are focusing on expanding their production capabilities, gaining WHO prequalification, and collaborating with global health agencies. Notable developments include:

2023: Pfizer expanded its production of WHO-prequalified Paromomycin for use in leishmaniasis treatment programs across Africa.

2024: Ipca Laboratories secured a supply agreement with the Leishmaniasis East Africa Platform (LEAP) for injectable Paromomycin.

2025: Cipla launched a new pediatric oral suspension formulation targeting amoebiasis treatment in rural Asia.

Scope of Work – Global Paromomycin (CAS 7542-37-2) Market

Key Market Developments

Pfizer Inc. expanded WHO-compliant Paromomycin supply for East African treatment programs.

Strides Pharma received regulatory approval in Southeast Asia for its generic oral Paromomycin tablets.

Lupin Pharmaceuticals initiated clinical trials for Paromomycin-based combination therapies in visceral leishmaniasis.

FAQs

1) What is the current market size of the Global Paromomycin (CAS 7542-37-2) Market?

The market was valued at USD 98.7 million in 2023.

2) What is the major growth driver of the Global Paromomycin (CAS 7542-37-2) Market?

The increasing prevalence of parasitic infections and global initiatives targeting neglected tropical diseases.

3) Which is the largest region during the forecast period in the Global Paromomycin (CAS 7542-37-2) Market?

Asia-Pacific leads the market due to high disease burden and established production infrastructure.

4) Which segment accounted for the largest market share in Global Paromomycin (CAS 7542-37-2) Market?

The oral formulation segment held the largest market share in 2023.

5) Who are the key market players in the Global Paromomycin (CAS 7542-37-2) Market?

Pfizer Inc., Ipca Laboratories Ltd., Cipla Ltd., Strides Pharma Science Ltd., and Endo International plc are major players.